These PD-1-targeted agents have found expansive application in the therapeutic landscape of SCLC, with pembrolizumab demonstrating noteworthy antitumor efficacy, particularly in patients harboring pretreated, PD-L1 expressing SCLC. Here, PDCD1 is linked to small cell lung carcinoma.